Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment.
G1 cytostatic drugs reduce CCR5 co-receptor expression and enhance the antiviral activity of a CCR5 antagonist in vitro. The administration of rapamycin, a G1 cytostatic agent, to three cynomolgous macaques led to decreased CCR5 messenger RNA expression in peripheral blood mononuclear cells and cervicovaginal tissue. These results support further clinical evaluation of G1 cytostatic agents such as rapamycin targeting the downregulation of CCR5 expression as a strategy for both the prevention and treatment of HIV infection.
Gilliam
Bruce L
BL
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Heredia
Alonso
A
Devico
Anthony
A
Le
Nhut
N
Bamba
Douty
D
Bryant
Joseph L
JL
Pauza
C David
CD
Redfield
Robert R
RR
D000818:Animals; D005260:Female; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008251:Macaca; D012333:RNA, Messenger / Q000378:metabolism*; D019713:Receptors, CCR5 / Q000235:genetics / Q000378:metabolism*; D020123:Sirolimus / Q000494:pharmacology*
D007166:Immunosuppressive Agents; D012333:RNA, Messenger; D019713:Receptors, CCR5; D020123:Sirolimus